Differences

This shows you the differences between two versions of the page.

--- history_of_vaccines [2021/11/18 21:47]
pamela
+++ history_of_vaccines [2021/11/21 00:44] (current)
pamela [History of Vaccines]
@@ Line 12: / Line 12: @@
 [[WHO]] VACCINE FACT BOOK - 2011
+===Timeline Vaccine Approvals===
+**1905**    U.S. Supreme Court upholds state law mandating smallpox vaccinations
+**1906 to 1928**    Vaccines against pertussis and diphtheria developed
+**1944**    Pertussis vaccine recommended for universal use in infants
+**1947**    DPT (tri-valent diphtheria/pertussis/tetanus) recommended by the AAP for routine use
+**1955**    IPV (inactivated polio vaccine) licensed (was later modified in 1987)
+**1961**    OPV (oral, live-virus polio vaccine) licensed
+**1963**    Measles vaccine licensed
+**1959 to 1968**    Quadrigen (DPT-IPV combo) used routinely [pulled off the market in1968 for safety and efficacy reasons]
+**1969**    Rubella vaccine licensed
+**1971**    MMR (tri-valent measles/mumps/rubella) licensed
+**1972**    U.S. ended routine use of smallpox vaccine
+**1981**    Japan licenses safer DPT vaccine, the acellular DTaP
+**1983 to 1985**    first Hib (Hemophilus influenza B) vaccine (taken off the market in1985 for safety and efficacy reasons)
+**1986**    [[Vaccine Injury Compensation Act]] passed
+**1986**    recombinant Hepatitis B vaccine licensed
+**1987**  Hib vaccine licensed
+**1988**    Hib added to schedule
+**1988**  Vaccine Injury Compensation Program Funded
+**1990**    conjugate Hib vaccine licensed
+**1991**    recombinant Hepatitis B recommended for all newborn infants and children
+**1993**    DPTH (DPT-Hib combo) licensed
+**1995**    Varicella licensed
+**1996**    Dtap licensed; recommended for use instead of whole-cell DPT
+**1996**    Hib-HepB combo licensed
+**1998**    Lyme vaccine (Lymerix) licensed
+**early 1998**    Rotavirus vaccine recommended by CDC for universal use in infants
+**Aug. 1998**    Rotavirus vaccine licensed
+**Oct. 1999**    Rotavirus vaccine pulled off the market due to significant adverse reactions
+**1999/2000**    A Joint Statement by the U.S. Public Health Service, the AAFP, the AAP, and ACIP urging manufacturers to remove the preservative thimerosal as soon as possible from vaccines routinely recommended for infants.
+**2000**   Prevnar (pneumococcal conjugate vaccine) licensed
+**2000**    CDC recommends use of IPV instead of OPV (polio vaccine)
+**2002**    GSK pulled Lymerix off the market
+**2002**    Pediarix (penta-valent DtaP/HepB/IPV) licensed
+**2002** CDC encourages flu vaccine for children
+**2003**   Inhaled flu vaccine (Flumist) being reviewed for approval by the FDA
+**2003**    Smallpox vaccine for first-responders
+https://web.archive.org/web/20030529035635/http://www.909shot.com/Timeline/timeline.htm
+**2004** [[Project BioShield]], a $5.6 billion program, established to speed the development of medical treatments for the effects of biological and other unconventional weapons.
+**2007** Apr 25, 2007 (CIDRAP News) Health and Human Services (HHS) plan for developing and buying medical countermeasures against a range of biological, chemical, and other threats, with new [[anthrax]] and [[smallpox vaccines]] among the near-term priorities.
+The 21-page implementation plan, released Apr 20 on the HHS Web site and in the Federal Register, details how the agency will **acquire countermeasures against 14 threats on its priority list**, which include nine category A biological agents, two category B biological agents, typhus, certain volatile nerve agents, and radiological and nuclear agents.
+https://web.archive.org/web/20070708144558/http://www.mvrd.org/BioShieldArchives.cfm
 ==== Vaccine Technological Development ====